stockportfolio.pro
Stocks / LBRX vs PHAT
LBRX vs PHAT
LB Pharmaceuticals Inc and Phathom Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| LB Pharmaceuticals Inc (LBRX) | Phathom Pharmaceuticals, Inc. (PHAT) | |
|---|---|---|
| Market cap | $0.8B | $0.8B |
| Revenue (latest FY) | $0 | $175.11M |
| Net income (latest FY) | $-25.20M | $-221.25M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | -126.3% |
| Return on equity | -8.4% | 50.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LBRX — free Open PHAT — freeFrequently asked questions
Which is bigger, LBRX or PHAT?
Phathom Pharmaceuticals, Inc. is larger by market capitalization — $0.8B versus $0.8B.
Which grows faster, LBRX or PHAT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.